Could a drug combo free liver transplant patients from lifelong pills?

NCT ID NCT06832189

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 28 times

Summary

This study tests whether two drugs, everolimus and epoetin, can help liver transplant patients safely stop taking their standard anti-rejection medication (tacrolimus). About 20 adults who are 1-10 years post-transplant and stable on tacrolimus will switch to everolimus, receive five doses of epoetin, and then slowly stop everolimus. The main goal is to see if this approach is safe and can lead to "operational tolerance"—meaning the body accepts the new liver without needing daily anti-rejection drugs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Northwestern University Feinberg School of Medicine

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California San Francisco School of Medicine

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pennsylvania Medical Center

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.